Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ANL-101
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : ANL Bio
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement covers process development for ANLBIO’s gene therapy vector, ANL-101, followed by 200 L scale production. The manufacturing part of the agreement covers upscaling of the process to working volume of 100s of liters and subsequent manufactu...
Brand Name : ANL-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 18, 2022
Lead Product(s) : ANL-101
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : ANL Bio
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
